Selective Expression of the Chemokine Receptor XCR1 on Cross-presenting Dendritic Cells Determines Cooperation with CD8 + T Cells

The expression of the chemokine receptor XCR1 and the function of its ligand XCL1 (otherwise referred to as ATAC, lymphotactin, or SCM-1) remained elusive to date. In the present report we demonstrated that XCR1 is exclusively expressed on murine CD8 + dendritic cells (DCs) and showed that XCL1 is a...

Full description

Saved in:
Bibliographic Details
Published in:Immunity (Cambridge, Mass.) Vol. 31; no. 5; pp. 823 - 833
Main Authors: Dorner, Brigitte G., Dorner, Martin B., Zhou, Xuefei, Opitz, Corinna, Mora, Ahmed, Güttler, Steffen, Hutloff, Andreas, Mages, Hans W., Ranke, Katja, Schaefer, Michael, Jack, Robert S., Henn, Volker, Kroczek, Richard A.
Format: Journal Article
Language:English
Published: United States Elsevier Inc 20-11-2009
Elsevier Limited
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The expression of the chemokine receptor XCR1 and the function of its ligand XCL1 (otherwise referred to as ATAC, lymphotactin, or SCM-1) remained elusive to date. In the present report we demonstrated that XCR1 is exclusively expressed on murine CD8 + dendritic cells (DCs) and showed that XCL1 is a potent and highly specific chemoattractant for this DC subset. CD8 + T cells abundantly secreted XCL1 8–36 hr after antigen recognition on CD8 + DCs in vivo, in a period in which stable T cell-DC interactions are known to occur. Functionally, XCL1 increased the pool of antigen-specific CD8 + T cells and their capacity to secrete IFN-γ. Absence of XCL1 impaired the development of cytotoxicity to antigens cross-presented by CD8 + DCs. The XCL1-XCR1 axis thus emerges as an integral component in the development of efficient cytotoxic immunity in vivo.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:1074-7613
1097-4180
DOI:10.1016/j.immuni.2009.08.027